HR and breast cancer: AR was most frequently expressed in BrM from HER2+ breast cancer (n = 21/28 BrM were AR+), followed by HR+/HER2− breast cancer (n = 9/17), and least frequently in TNBC (n = 2/12) (p = 0.003) (Figure 1b).